Drugs / XMT-1522
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02952729 | Nov 2016 → Jan 2019 | female breast carcinoma, gastric cancer, non-small cell lung carcinoma | Mersana Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-02-03 | Takeda | Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522 takeda.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XMT-1522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02952729 ↗ |
| Route | Intravenous | “XMT-1522 administered as an intravenous infusion once every three weeks.” NCT02952729 ↗ |